Skip to main content

Table 3 Meta-regression analysis for the effect of metformin on SMCC of cardiovascular parameters and NT-ProBNP

From: Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials

 

LVMI

LVEF

E/e′ ratio

NT-ProBNP/BNP

B [95% CI]

p

B [95% CI]

p

B [95% CI]

p

B [95% CI]

p

Intercept only model

 − 0.49 [− 0.94; − 0.04]

0.036

0.128 [–0.19; 0.45]

0.45

–0.18 [− 0.387; 0.03]

0.07

 − 0.07 [− 0.28; 0.14]

0.44

Metformin dose

 1000 mg or less

 − 0.287 [–0.7; 0.134]

0.14

–0.23 [− 0.49; 0.03]

0.07

 − 0.128 [− 0.59; 0.34]

0.36

NA

 

  > 1000 mg

 − 0.7 [− 1.51;0.11]

0.08

0.28 [0.04; 0.52]

0.04

 − 0.313 [− 1.2; 0.56]

0.26

 − 0.02 [− 0.44; 0.41]

0.92

Duration

 6 months or less

 − 0.215 [− 0.51; 0.08]

0.12

 − 0.02 [− 0.48; 0.43]

0.9

 − 0.163 [− 0.5; 0.17]

0.17

 − 0.05 [− 0.5; 0.41]

0.79

  > 6 months

 − 0.4 [− 0.78; − 0.02]

0.04

0.3 [− 0.07; 0.68]

0.09

NA

 

 − 0.07 [− 0.36; 0.21]

0.53

HF

 No

 − 0.51 [− 1.1; 0.08]

0.09

0.06 [− 0.5; 0.62]

0.81

 − 0.19 [− 0.73; 0.36]

0.28

 − 0.04 [− 0.26; 0.19]

0.68

 Yes

NA

 

0.23 [0.1; 0.36]

0.004

NA

 

 − 0.08 [− 0.73; 0.56]

0.74

Pooled baseline average (1 unit increase)

0.005 [− 0.02; 0.03]

0.64

 − 0.005 [− 0.02; 0.01]

0.34

0.05 [− 0.13; 0.23]

0.35

0.09 ¶ [− 0.05; 0.06]

0.69

  1. Bold values denote statistical significance at the p < 0.05 level
  2. B—regression coefficient (SMCC), CI.L—lower limit for 95% confidence interval, CI.U—upper limit for the 95% confidence interval
  3. HF heart failure
  4. NA: Only one study provided data
  5. ¶Result represents the change in SMCC for each 100-unit increase